Impact and Effectiveness of Monovalent Rotavirus Vaccine in Armenian Children | Zendy

Gayane Sahakyan | Zendy; Svetlana Grigoryan | Zendy; Annemarie Wasley | Zendy; Liudmila Mosina | Zendy; Shushan Sargsyan | Zendy; Ara Asoyan | Zendy; Zaruhi Gevorgyan | Zendy; Karine Kocharyan | Zendy; Tigran Avagyan | Zendy; Benjamin A. Lopman | Zendy; Artavazd Vanyan | Zendy; Sergey Khactatryan | Zendy; Umesh D. Parashar | Zendy; Margaret M. Cortese | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact and Effectiveness of Monovalent Rotavirus Vaccine in Armenian Children

Author(s) -

Gayane Sahakyan,

Svetlana Grigoryan,

Annemarie Wasley,

Liudmila Mosina,

Shushan Sargsyan,

Ara Asoyan,

Zaruhi Gevorgyan,

Karine Kocharyan,

Tigran Avagyan,

Benjamin A. Lopman,

Artavazd Vanyan,

Sergey Khactatryan,

Umesh D. Parashar,

Margaret M. Cortese

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw045

Subject(s) - medicine , rotavirus , rotavirus vaccine , pediatrics , confidence interval , immunization , disease burden , vaccination , diarrhea , disease , immunology , antigen

The Republic of Armenia was 1 of the 2 earliest countries in the Newly Independent States to introduce rotavirus vaccine into its national immunization program to reduce the burden of rotavirus disease (documented to cause 38% of acute gastroenteritis hospitalizations [AGE] among children aged <5 years). In November 2012, RV1 (Rotarix) was introduced for Armenian infants at ages 6 and 12 weeks.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research